Please assess the completion status of the following clinical trial:

Trial Title: Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Male or female patient diagnosed with FECD and corneal edema evident by slit lamp exam and/or corneal tomography.~* Patient is able and willing to administer eye drops.~* Patient is able to comprehend and has signed the Informed Consent form.~Exclusion Criteria:~* Active intraocular inflammation, corneal ulceration, keratitis, or conjunctivitis.~* Known sensitivity to any of the ingredients in the study medications.~* Abnormal eyelid function.~* History of herpetic keratitis.~* History of non-compliance with using prescribed medication.~* Current or planned pregnancy within the study duration.~* Concurrent involvement or participation in another randomized clinical trial within 30 days prior to enrollment in this study.~* Any ocular or systemic condition (i.e., UNCONTROLLED systemic disease) or situation which in the investigator's opinion may put the patient at significant risk, confound the study results, or interfere significantly with the patient's participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Netarsudil (Type: ACTIVE_COMPARATOR): A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.
- Placebo (Type: PLACEBO_COMPARATOR): A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.

Based on this trial design, predict the completion outcome and termination type (if applicable).